27 Stocks Moving in Monday’s Pre-Market Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday.
SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $9
SVB Leerink analyst Roanna Ruiz maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Market Perform and lowers the price target from $10 to $9.
Atea Pharmaceuticals Q4 EPS $1.34 Beats $0.17 Estimate, Sales $192.20M Beat $85.73M Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $0.17 by 688.24 percent. This is a 41.05 percent increase over earnings of $0.95 per share
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Atea Pharma Highlights 2022 Strategic Priorities
COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials
HCV: Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase
